Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 979

1.

Hypertension control and care at Mulago Hospital ambulatory clinic, Kampala-Uganda.

Ssinabulya I, Nabunnya Y, Kiggundu B, Musoke C, Mungoma M, Kayima J.

BMC Res Notes. 2016 Nov 17;9(1):487.

2.

Drug Treatment of Hypertension: Focus on Vascular Health.

Cameron AC, Lang NN, Touyz RM.

Drugs. 2016 Oct;76(16):1529-1550. Review.

PMID:
27667708
3.

JS ISH-ESH-4 WHAT DO CLINICAL TRIALS TEACH US ABOUT SELECTION OF ANTIHYPERTENSIVE DRUGS.

Cushman WC.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e193.

PMID:
27754008
4.

Complement activation and effect of eculizumab in scleroderma renal crisis.

Devresse A, Aydin S, Le Quintrec M, Demoulin N, Stordeur P, Lambert C, Gastoldi S, Pirson Y, Jadoul M, Morelle J.

Medicine (Baltimore). 2016 Jul;95(30):e4459. doi: 10.1097/MD.0000000000004459.

5.

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Ahmed A, Jorna T, Bhandari S.

Nephron. 2016;133(3):147-58. doi: 10.1159/000447068. Epub 2016 Jun 24. Review.

6.

Update in Hypertension Therapy.

Mankin LA.

Med Clin North Am. 2016 Jul;100(4):665-93. doi: 10.1016/j.mcna.2016.03.005. Review.

PMID:
27235610
7.

Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.

Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, Khouzam RN.

Am J Med Sci. 2016 Mar;351(3):309-16. doi: 10.1016/j.amjms.2015.12.021. Review.

PMID:
26992264
8.

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Hubers SA, Brown NJ.

Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Review.

9.

Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.

PLoS Med. 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. eCollection 2016 Mar 8. Review. Erratum in: PLoS Med. 2016 Jun;13(6):e1002064.

10.

Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.

Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):471-80. doi: 10.2215/CJN.04660415. Epub 2016 Feb 18.

11.

Baseline Characteristics and Prescription Patterns of Standard Drugs in Patients with Angiographically Determined Coronary Artery Disease and Renal Failure (CAD-REF Registry).

Reinecke H, Breithardt G, Engelbertz C, Schmieder RE, Fobker M, Pinnschmidt HO, Schmitz B, Bruland P, Wegscheider K, Pavenstädt H, Brand E.

PLoS One. 2016 Feb 9;11(2):e0148057. doi: 10.1371/journal.pone.0148057. eCollection 2016 Feb 9.

12.

Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.

Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ, Shi XY.

Cochrane Database Syst Rev. 2016 Jan 27;(1):CD009210. doi: 10.1002/14651858.CD009210.pub2. Review.

PMID:
26816003
13.

[Cardio-Nephroprotection--the Most Important Goal of Antihypertensive Therapy in Patients With Type 2 Diabetes].

Statsenko ME, Derevyanchenko MV.

Kardiologiia. 2015;55(8):43-8. Russian.

PMID:
26761971
14.

Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.

Tang CH, Wang CC, Chen TH, Hong CY, Sue YM.

J Am Heart Assoc. 2016 Jan 6;5(1). pii: e002584. doi: 10.1161/JAHA.115.002584.

15.

New therapies for arterial hypertension.

Pagliaro B, Santolamazza C, Rubattu S, Volpe M.

Panminerva Med. 2016 Mar;58(1):34-47. Epub 2016 Jan 5. Review.

PMID:
26730462
16.

Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.

Hsiao FC, Tung YC, Chou SH, Wu LS, Lin CP, Wang CL, Lin YS, Chang CJ, Chu PH.

Medicine (Baltimore). 2015 Dec;94(51):e2355. doi: 10.1097/MD.0000000000002355.

17.

Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.

Terano C, Ishikura K, Miura M, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Ando T, Honda M.

Eur J Pediatr. 2016 May;175(5):631-7. doi: 10.1007/s00431-015-2680-8. Epub 2015 Dec 21.

PMID:
26687571
18.

[Prophylaxis of sudden cardiac death in patients with chronic kidney disease].

Łagodziński A, Wranicz JK.

Pol Merkur Lekarski. 2015 Nov;39(233):329-32. Review. Polish.

PMID:
26637101
19.
20.

Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J.

Am J Manag Care. 2015 Sep;21(11 Suppl):S212-20.

Supplemental Content

Loading ...
Support Center